Press Releases
May 28, 2020
Surface Oncology Announces Change to Location and Format of 2020 Annual Meeting of Stockholders
May 20, 2020
Surface Oncology Fully Utilizes its $30M At-the-Market Facility
May 20, 2020
Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
May 15, 2020
Surface Oncology to Present Preclinical Data for Multiple Product Programs at the American Association for Cancer Research Annual Meeting
May 14, 2020
Surface Oncology to Present at the American Society of Clinical Oncology Annual Meeting
May 13, 2020
Surface Oncology to Present at the UBS Virtual Global Healthcare Conference
May 12, 2020
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2020
April 23, 2020
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Antibody SRF388
March 17, 2020
Surface Oncology Announces First Patient Dosed in Clinical Trial of Immuno-Oncology Candidate SRF617
March 10, 2020
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2019
Displaying 1 - 10 of 12